Infarct Volume as a Surrogate or Auxiliary Outcome Measure in Ischemic Stroke Clinical Trials | Zendy

Jeffrey L. Saver | Zendy; Karen C. Johnston | Zendy; Daniel Homer | Zendy; Robert J. Wityk | Zendy; Walter J. Koroshetz | Zendy; Laura L. Truskowski | Zendy; E. Clarke Haley | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Infarct Volume as a Surrogate or Auxiliary Outcome Measure in Ischemic Stroke Clinical Trials

Author(s) -

Jeffrey L. Saver,

Karen C. Johnston,

Daniel Homer,

Robert J. Wityk,

Walter J. Koroshetz,

Laura L. Truskowski,

E. Clarke Haley

Publication year - 1999

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/01.str.30.2.293

Subject(s) - medicine , stroke (engine) , interquartile range , surrogate endpoint , clinical trial , cardiology , infarction , glasgow outcome scale , cerebral infarction , randomized controlled trial , brain ischemia , surgery , ischemia , myocardial infarction , glasgow coma scale , mechanical engineering , engineering

Reduction in infarct volume is the standard measure of therapeutic success in animal stroke models. Reduction in infarct volume has been advocated as a biological surrogate or auxiliary outcome measure for human stroke clinical trials to replace or supplement deficit, disability, and global clinical scales. However, few studies have investigated correlations between infarct volume and clinical end points in acute ischemic stroke patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research